Trexquant Investment LP Buys 16,248 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Trexquant Investment LP raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 105,528 shares of the company's stock after buying an additional 16,248 shares during the quarter. Trexquant Investment LP owned 0.22% of Amphastar Pharmaceuticals worth $3,918,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. TD Private Client Wealth LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after purchasing an additional 388 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after buying an additional 398 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after buying an additional 493 shares during the period. KBC Group NV increased its position in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after acquiring an additional 650 shares in the last quarter. Finally, Sanctuary Advisors LLC raised its holdings in shares of Amphastar Pharmaceuticals by 8.5% during the third quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company's stock worth $466,000 after acquiring an additional 801 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several research firms have issued reports on AMPH. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday.

Amphastar Pharmaceuticals Stock Down 9.2 %

NASDAQ:AMPH traded down $2.33 on Thursday, hitting $22.91. 203,714 shares of the company's stock were exchanged, compared to its average volume of 453,903. The company has a market cap of $1.09 billion, a P/E ratio of 7.67, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The firm has a 50-day moving average price of $29.06 and a 200-day moving average price of $38.46. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.89 and a 52 week high of $53.96.

Insider Buying and Selling

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 27.10% of the stock is currently owned by corporate insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.